Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LSL Pharma GroupTSXV:LSL -1.56%49 3-Year Book Growth Rate is 49.30% as of Jun. 2026, which is 193% above its 10-year median of 16.80. GuruFocus rates TSXV:LSL with a GF Score™ of 49/100 and a GF Value™ of C$0.80 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 912 Drug Manufacturers companies, LSL Pharma Group ranks better than 94.96% on this metric.
During the past 12 months, LSL Pharma Group's average Book Value per Share Growth Rate was -18.00% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 49.30% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 19.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 7 years, the highest 3-Year average Book Value per Share Growth Rate of LSL Pharma Group was 49.30% per year. The lowest was 4.90% per year. And the median was 16.80% per year.
LSL Pharma Group (TSXV:LSL) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
LSL Pharma Group 3-Year Book Growth Rate Related Terms
TSXV:LSL vs ZTS: 3-Year Book Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, LSL Pharma Group's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LSL Pharma Group 3-Year Book Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, LSL Pharma Group's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where LSL Pharma Group's 3-Year Book Growth Rate falls into.
LSL Pharma Group 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 49.30% mean?
LSL Pharma Group (TSXV:LSL) has a 3-Year Book Growth Rate of 49.30% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for LSL Pharma Group and its competitors. This is 193% above median its historical median of 16.80. Over the past decade, LSL Pharma Group's 3-Year Book Growth Rate has ranged from 4.90 to 49.30. According to the industry distribution chart, LSL Pharma Group ranks #46 out of 912 companies in the Drug Manufacturers industry, placing it in the top 5%.
Is LSL Pharma Group's 3-Year Book Growth Rate too high?
LSL Pharma Group's current 3-Year Book Growth Rate of 49.30% is 193% above median its 10-year median of 16.80. Over the past 10 years, this metric has ranged from a low of 4.90 to a high of 49.30. The Drug Manufacturers industry median 3-Year Book Growth Rate is 4.60. LSL Pharma Group's value of 49.30% is 971.7% above this industry median. Based on the distribution chart, LSL Pharma Group ranks #46 out of 912 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, LSL Pharma Group has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does LSL Pharma Group's 3-Year Book Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, LSL Pharma Group ranks #46 out of 912 companies for 3-Year Book Growth Rate. This places LSL Pharma Group in the top 5% of its industry — outperforming the majority of peers. The industry median 3-Year Book Growth Rate is 4.60. LSL Pharma Group's value of 49.30% is 971.7% above this benchmark. Historically, LSL Pharma Group's own 3-Year Book Growth Rate has ranged from 4.90 to 49.30 over the past decade. While the company's 10-year median is 16.80 vs. the industry median of 4.60, LSL Pharma Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.60, based on 912 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LSL Pharma Group's current 3-Year Book Growth Rate of 49.30% is 971.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for LSL Pharma Group and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LSL Pharma Group's current 3-Year Book Growth Rate is 49.30%, which is 193% above median its own 10-year median of 16.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LSL Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, LSL Pharma Group (TSXV:LSL) is currently considered Possible Value Trap. The stock's GF Value™ is C$0.80, compared to a current price of C$0.33 — trading 58.8% below its estimated fair value. The current 3-Year Book Growth Rate is 49.30%, which is 193% above median its 10-year median of 16.80 and 971.7% above the Drug Manufacturers industry median of 4.60. LSL Pharma Group's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For LSL Pharma Group (TSXV:LSL), the current 3-Year Book Growth Rate is 49.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LSL Pharma Group (TSXV:LSL) Overvalued in 2026?
Based on GuruFocus' analysis, LSL Pharma Group stock appears to be undervalued.
The current stock price of C$0.33 is trading 58.8% below its estimated GF Value™ of C$0.80.
GuruFocus considers LSL Pharma Group to be Possible Value Trap.
Key valuation signals for TSXV:LSL:
3-Year Book Growth Rate: 49.30% (193% above median its 10-year median of 16.80)
GF Value™: C$0.80 vs. price of C$0.33 (58.8% below fair value)
Industry Position: 971.7% above the Drug Manufacturers median (#46 of 912)
No single metric tells the full story. See the TSXV:LSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LSL Pharma Group Inc develops, manufactures and commercializes sterile pharmaceutical products, cosmetic products and natural health products. It operates in three segments CMO activities include four operating entities LSL Laboratory, Dermolab, Du-Var, and VSI; Integrated Eye-care pharmaceutical company which includes sterile Eye-care manufacturing operation; and Private Label Business includes Juno OTC which commercializes pharmaceutical products with a focus on private label, over the counter (OTC) products. It derives majority of revenue from CMO activities segment.
49GF Score
Get the complete analysis for TSXV:LSL
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:LSL has been successfully added to your 
